Al Sandrock makes his first post-Biogen move, joining turnaround effort at a troubled gene therapy startup
A few years ago, when Biogen was looking for its next blockbuster, the biotech reportedly considered buying out Voyager Therapeutics.
The deal made intuitive sense. Voyager focused on gene therapies for neurological conditions, combining a technology in which Biogen had shown occasional enthusiasm with a field in which Biogen considered themselves the leading expert. But, as STAT reported last year, Biogen’s conservative board nixed it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.